Clinical Study
Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)
Table 4
Incidences of AEs during the 18-month follow-up period (safety set).
| Preferred term, (%) | Unilateral DME () | Bilateral DME () |
| Any AE | 12 (7.64) | 49 (10.77) | Blood and lymphatic system disorders | 0 | 1 (0.22) | Cardiac disorders | 2 (1.27) | 6 (1.32) | Eye disorders (mainly cataract, conjunctival hemorrhage, and diabetic retinal edema being the major) | 5 (3.18) | 19 (4.18) | General disorders and administration site conditions | 0 | 2 (0.44) | Infections and infestations | 0 | 8 (1.76) | Injury, poisoning, and procedural complications | 0 | 3 (0.66) | Investigations | 0 | 1 (0.22) | Metabolism and nutrition disorders | 0 | 1 (0.22) | Musculoskeletal and connective tissue disorders | 0 | 1 (0.22) | Neoplasms benign, malignant, and unspecified (including cysts and polyps) | 1 (0.64) | 4 (0.88) | Nervous system disorders | 2 (1.27) | 5 (1.10) | Psychiatric disorders | 0 | 1 (0.22) | Renal and urinary disorders | 1 (0.64) | 2 (0.44) | Respiratory, thoracic, and mediastinal disorders | 1 (0.64) | 1 (0.22) | Skin and subcutaneous tissue disorders | 0 | 1 (0.22) | Surgical and medical procedures | 0 | 4 (0.88) | Vascular disorders | 1 (0.64) | 3 (0.66) |
|
|
AE, adverse event; DME, diabetic macular edema.
|